EPCLUSA is indicated for the treatment of adults with chronic hepatitis C virus (HCV) GT 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.

TREAT WITH BROAD COVERAGE.

EPCLUSA HAS BROAD
COVERAGE AND
PATIENT SUPPORT1

EPCLUSA
HAS BROAD
COVERAGE AND
PATIENT SUPPORT1

BROADEST COVERAGE AMONG COMMERCIAL AND MEDICARE PLANS OF ANY PANGENOTYPIC REGIMEN1

Many patients may have dual eligibility for
Medicare and
Medicaid coverage1

Use the tool below to find out about coverage in your area

Formulary information provided by Fingertip Formulary® and is current as of . Because formularies do change and many health plans offer more than one formulary, please check with the health plan directly to confirm coverage for individual patients.


EPCLUSA
Sofosbuvir/ Velpatasvir
(authorized generic of EPCLUSA)

*Coverage status may vary by genotype.

Exclusive = is on formulary while other direct-acting antivirals (DAAs) are not, has a lower tier status than other DAAs, or is required in a step therapy process vs other DAAs.

Preferred = shares the lowest tier status with at least one direct-acting antiviral.

Non-Preferred = another direct-acting antiviral has a lower tier status or is required in a step therapy process.

Not Available = formulary status information not available.

Not Covered = the product is not on the preferred drug list for the health plan.


Sofosbuvir/velpatasvir (authorized generic of EPCLUSA) is marketed by Asegua Therapeutics LLC, an affiliate of Gilead.

Click here for patient support services, which may assist in identifying coverage options for your patients.

The references to company/plan names listed do not, in any manner, imply an endorsement of EPCLUSA or any other products by the referenced companies/plans.

Placement on the formulary is not intended to imply any claims regarding safety or efficacy of the products referenced.

$5 co-pay for eligible patients

$5 CO-PAY COUPON

Cost should not be a barrier to treatment. Help patients register for a co-pay coupon

A co-pay coupon may help eligible patients reduce out-of-pocket costs of Gilead treatment.

 

  • Eligible patients may pay as little as $5 per co-pay for their medicine. Patients are not eligible if they are enrolled in a government healthcare prescription drug program such as Medicare Part D or Medicaid (including patients who are in the coverage gap known as the “donut hole”)
  • If patients are eligible, the co-pay coupon program will cover the out-of-pocket costs for EPCLUSA prescriptions up to a maximum of 25% of the catalog price of a 12-week regimen

HAVE A PATIENT
STARTING TREATMENT?

Support Path® is here to help

Support Path can help patients understand insurance coverage and financial support options to get started on treatment.

 

Visit MySupportPath.com now ▸

mysupportpath.com

1-855-7-MYPATH

(1-855-769-7284)

▲ Back to top

GT = genotype

GT = genotype

REFERENCE:
  1. Data on file. Gilead Hepatitis C Virus Coverage Status Report. March 4, 2019.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

Contraindications

  • If EPCLUSA is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.

Warnings and Precautions

  • Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir containing regimen. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of EPCLUSA with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.

Adverse Reactions

  • The most common adverse reactions (10%, all grades) with EPCLUSA were headache and fatigue; and when used with RBV in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Drug Interactions

  • Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan.
  • Coadministration of EPCLUSA is not recommended with proton-pump inhibitors, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir.

Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.

Please see full Prescribing Information for EPCLUSA, including BOXED WARNING.

The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences, as regulatory control, legal requirements, and/or medical practices may vary in other countries.

Gilead corporate logo

Photos not of actual patients.

EPCLUSA, the EPCLUSA logo, SUPPORT PATH, GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.

©2019 Gilead Sciences, Inc. All rights reserved. EPCP0400 06/19